SOURCE-LINKED STUDY SUMMARY
MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study.
Abstract summarizedQuality not appraised
- What was studied
- This phase 2b trial tested whether MK-0677 improved functional recovery and raised IGF-1 after hip fracture.
- Who / model studied
- The study randomized 123 older patients recovering from hip fracture.
- Studied dose & schedule
- Participants received MK-0677 25 mg daily or placebo for 24 weeks; the abstract did not specify the route.
- What the study found
- Gait speed improved versus placebo, but stair-climbing power and several other functional measures did not. IGF-1 rose by 51.4 ng/mL.
- Limitations & context
- The trial ended early after a congestive-heart-failure safety signal; investigators judged MK-0677’s safety profile unfavorable in this population.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/j.archger.2010.10.004